Form 4: Corcept Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 40,000 shares of common stock on July 15, 2026.
Summary
- Option exercise/conversion: acquired 15,833 Common Stock at $19.26 ($304,944) on July 15, 2026; holds 31,963 after (Direct).
- Option exercise/conversion: acquired 24,167 Common Stock at $23.06 ($557,291) on July 15, 2026; holds 56,130 after (Direct).
- Open-market sale: disposed of 7,919 Common Stock at $86.78 ($687,179) on July 15, 2026; holds 48,211 after (Direct).
- Open-market sale: disposed of 28,460 Common Stock at $87.89 ($2,501,244) on July 15, 2026; holds 19,751 after (Direct).
- Open-market sale: disposed of 3,520 Common Stock at $88.30 ($310,822) on July 15, 2026; holds 16,231 after (Direct).
- Open-market sale: disposed of 101 Common Stock at $89.43 ($9,032) on July 15, 2026; holds 16,130 after (Direct).
- Option exercise/conversion: disposed of 15,833 Stock option (right to buy) on July 15, 2026; holds 4,167 after (Direct).
- Option exercise/conversion: disposed of 24,167 Stock option (right to buy) on July 15, 2026; holds 175,833 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,508,277 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Atabak Mokari — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-15 | Option exercise/conversion | Common Stock | 15,833 | $19 | $304.9K | 31,963 |
| 2026-07-15 | Option exercise/conversion | Common Stock | 24,167 | $23 | $557.3K | 56,130 |
| 2026-07-15 | Open-market sale | Common Stock | 7,919 | $87 | $687.2K | 48,211 |
| 2026-07-15 | Open-market sale | Common Stock | 28,460 | $88 | $2.5M | 19,751 |
| 2026-07-15 | Open-market sale | Common Stock | 3,520 | $88 | $310.8K | 16,231 |
| 2026-07-15 | Open-market sale | Common Stock | 101 | $89 | $9.0K | 16,130 |
| 2026-07-15 | Option exercise/conversion | Stock option (right to buy) | 15,833 | — | — | 4,167 |
| 2026-07-15 | Option exercise/conversion | Stock option (right to buy) | 24,167 | — | — | 175,833 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Option exercise/conversion (15,833 shares) |
| 2026-07-15 | Option exercise/conversion (24,167 shares) |
| 2026-07-15 | Open-market sale (7,919 shares) |
| 2026-07-15 | Open-market sale (28,460 shares) |
| 2026-07-15 | Open-market sale (3,520 shares) |
| 2026-07-15 | Open-market sale (101 shares) |
| 2026-07-15 | Option exercise/conversion (15,833 shares) |
| 2026-07-15 | Option exercise/conversion (24,167 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Atabak Mokari
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.